Search the Community
Showing results for tags 'Sequencing'.
Found 2 results
With increasing options to treat advanced prostate cancer, there is no clear agreement on the order in which these treatments should be given. I attach a chart prepared (following the STAMPEDE clinical trial which recommended early ADT and chemotherapy for certain patients) by an American oncologist setting out his view of what is currently best clinical practice in America. In Australia our options are more restricted: Abiraterone and Enzalutamide are only available on the Pharmaceutical Benefits Scheme after chemotherapy and Provenge is not available on the Pharmaceutical Benefits Scheme. Oldtimer's Disease - I can't remember which publication I found this table in. A prize for anyone who can tell me where it came from.
A Youtube video from the Mini Medical School for the Public series from the University of California San Francisco Patients with advanced prostate cancer are currently treated with combinations and sequences of immunotherapies, hormonal approaches and chemotherapy. Professor Charles Ryan, a medical oncologist at the University of California San Francisco covers the clinical and biological factors that drive treatment choice and sequence by physicians, and highlights how prostate cancer therapies are emblematic of the progress that is being made against cancer in general. Further, he addresses the challenges faced by patients and doctors and the research being done to address them. http://youtu.be/kQ4im2WQ75E [Although the talk was given in June 2014, most of it is still current as at October 2015]